Who Qualifies for GLP-1? BMI & Eligibility Criteria

The question "do I qualify for a GLP-1 medication" sounds as though it should have a single, crisp answer — a number you either clear or you don't. In practice it has at least three answers that often diverge: whether you meet the clinical criteria a prescriber uses, whether you fall within the indication a given brand is licensed for, and whether your insurer will pay. A person can satisfy the first two and be defeated by the third, or clear the medical bar comfortably while their particular brand of interest is approved only for a condition they don't have. Understanding eligibility means holding these layers apart rather than collapsing them into one.

This guide sets out how eligibility is actually defined — the body-mass-index thresholds, the role of weight-related conditions, the difference between the weight-management and type-2-diabetes indications, the brand-by-brand variation, and the contraindications that take a person out of contention regardless of BMI. It is descriptive, not prescriptive: nothing here is medical advice, and the decision to start one of these medications belongs with a clinician who knows your history. The aim is to let you walk into that conversation already understanding the framework the clinician is working within. The underlying biology of how these drugs work, which informs why the thresholds sit where they do, is covered in the GLP-1 science pillar; what follows assumes that mechanism and focuses on access.

How Eligibility Is Defined Clinically

GLP-1 receptor agonists are approved for two broad purposes, and the criteria differ depending on which one applies. The first is chronic weight management, where the medication is prescribed to treat overweight or obesity as conditions in their own right. The second is type 2 diabetes, where the same molecules — often under different brand names — are prescribed to improve blood-sugar control, with weight loss as a frequent and welcome secondary effect. The distinction matters enormously for eligibility, because the two indications use different criteria, carry different brand labels, and are treated very differently by insurers.

For the weight-management indication, eligibility is built around body mass index. The standard framework, now widely adopted in obesity medicine, sets two entry points. A person with a BMI of 30 or higher — the conventional threshold for obesity — generally qualifies on BMI alone. A person with a BMI of 27 or higher qualifies if they also carry at least one weight-related health condition. This second route recognises that the medical risk of excess weight is not a pure function of the number on the scale: someone at a BMI of 28 with type 2 diabetes and high blood pressure may stand to benefit more than someone at 31 with no metabolic complications at all.

For the type 2 diabetes indication, BMI is not the gatekeeper. Eligibility there follows from the diabetes diagnosis itself and the treatment goals a clinician sets for blood-sugar control, often after or alongside other glucose-lowering medications. A person with type 2 diabetes can be eligible for a GLP-1 agonist at a BMI well below the weight-management thresholds, because the drug is being prescribed to manage their glucose, not primarily their weight. This is why two people can both be "on Ozempic" for entirely different licensed reasons.

It is worth naming the conceptual shift underneath these criteria. The framework treats obesity as a chronic medical condition warranting treatment, rather than a lifestyle problem to be resolved by effort alone. The American Medical Association formally recognised obesity as a disease in 2013, and the eligibility thresholds reflect that stance: at a BMI of 30, or 27 with complications, the contribution of dysregulated appetite and metabolic biology is judged substantial enough that medical treatment is a reasonable first-line option rather than a last resort. The trial evidence underpinning that judgement is strong — in the STEP 1 trial, Wilding and colleagues (2021) reported mean weight loss of roughly 15% over 68 weeks on semaglutide, and in SURMOUNT-1, Jastreboff and colleagues (2022) reported up to about 21% on high-dose tirzepatide — magnitudes that reset what medication was expected to achieve.

BMI Thresholds and Comorbidities

The BMI thresholds are simple to state but carry several wrinkles worth understanding. BMI itself is weight in kilograms divided by height in metres squared, and it is a population-level screening tool rather than a precise measure of any individual's body composition. A very muscular person can have a high BMI without excess fat; an older person who has lost muscle can have a "normal" BMI while carrying metabolically active visceral fat. Good prescribers treat BMI as the entry criterion the guidelines and labels specify, while reading it in the context of the whole person — waist circumference, metabolic markers, and medical history all inform the judgement that the number alone cannot.

The weight-related conditions that open the BMI-27 route are the conditions for which excess weight is an established driver or aggravator. The commonly recognised ones include type 2 diabetes, prediabetes, hypertension (high blood pressure), dyslipidaemia (abnormal cholesterol or triglycerides), cardiovascular disease, obstructive sleep apnoea, and non-alcoholic fatty liver disease. Some frameworks also count osteoarthritis with a weight component, polycystic ovary syndrome, and gastro-oesophageal reflux. The presence of any one of these, alongside a BMI of 27 or above, typically satisfies the clinical criterion for the weight-management indication.

There is an important and increasingly recognised dimension here: cardiovascular benefit independent of weight. A large cardiovascular outcomes trial in people with overweight or obesity and established cardiovascular disease, but without diabetes, reported that semaglutide reduced major adverse cardiovascular events compared with placebo — the first demonstration that a weight-management GLP-1 agonist delivers a hard cardiovascular benefit beyond the weight loss itself. This finding has begun to reshape eligibility thinking, supporting access for people whose primary indication is cardiovascular risk reduction rather than weight per se. (The specific outcome figures sit outside the verified reference set used in this guide, so the conclusion is described in general terms; the headline — a reduction in cardiovascular events — is well established.)

The Eligibility Criteria at a Glance

The table below summarises the typical criteria across the two main indications and the leading brands. These are general thresholds drawn from standard labelling and obesity-medicine practice; exact wording varies by country, regulator, and product, and individual clinical judgement always applies.

Indication / brand	Typical BMI threshold	Comorbidity rules	Age	Notes
Weight management (general framework)	≥30, or ≥27 with a weight-related condition	BMI-27 route requires ≥1 condition (e.g. type 2 diabetes, hypertension, dyslipidaemia, sleep apnoea, cardiovascular disease)	Adults; some products extended to adolescents 12+	BMI is an entry criterion read alongside the whole clinical picture
Wegovy (semaglutide, weight)	≥30, or ≥27 with a condition	Comorbidity required at the 27 threshold	Adults; also approved for adolescents 12+ at the ≥95th percentile	Same molecule as Ozempic, higher dosing, weight label
Zepbound (tirzepatide, weight)	≥30, or ≥27 with a condition	Comorbidity required at the 27 threshold	Adults	Dual GLP-1/GIP agonist; largest average loss in trials
Saxenda (liraglutide, weight)	≥30, or ≥27 with a condition	Comorbidity required at the 27 threshold	Adults; adolescent 12+ approval exists	Daily injection; more modest loss, largely superseded
Type 2 diabetes (Ozempic, Mounjaro, Victoza, Rybelsus)	No BMI threshold	Confirmed type 2 diabetes; choice guided by glucose goals and other therapy	Adults	Weight loss is a secondary effect; BMI not the gatekeeper
All indications — exclusions	—	Personal/family history of medullary thyroid carcinoma or MEN2 is a contraindication; caution with pancreatitis history	—	Not for use in pregnancy; see contraindications below

Brand-by-Brand Differences

Much of the confusion around eligibility comes from the fact that the same molecules are sold under different names for different indications. The active ingredient may be identical; the brand, the licensed use, and therefore who qualifies, differ. A short map clears most of the fog. A fuller account of the medication class sits in what GLP-1 medication is.

Semaglutide is sold as Ozempic (injectable, licensed for type 2 diabetes), Wegovy (the same molecule at higher doses, licensed for weight management), and Rybelsus (an oral tablet, licensed for type 2 diabetes). If your goal is weight management and you do not have diabetes, the on-label semaglutide product is Wegovy, and your eligibility runs through the BMI thresholds. If you have type 2 diabetes, Ozempic or Rybelsus may be prescribed on the diabetes label, with eligibility following from that diagnosis.

Tirzepatide, the dual GLP-1/GIP agonist, is sold as Mounjaro for type 2 diabetes and Zepbound for weight management. The same molecular split applies: Zepbound's eligibility runs through the weight thresholds, Mounjaro's through the diabetes diagnosis. Tirzepatide produced the largest average weight loss in the head-to-head trial era, which is part of why demand — and the access pressure that follows it — has been intense.

Liraglutide, an earlier daily-injection agent, is sold as Victoza for diabetes and Saxenda for weight management. It produces more modest weight loss than the weekly agents and has largely been superseded for new prescriptions, though it retains a role in particular situations. Its eligibility criteria mirror the framework above.

The practical upshot is that "qualifying for a GLP-1" is really "qualifying for a specific product on a specific label." A person without diabetes who clears a BMI of 31 qualifies for Wegovy or Zepbound on the weight label, but would not be an on-label candidate for Ozempic or Mounjaro, even though those contain the same active drugs. Choosing among the brands is a clinical decision shaped by indication, tolerability, access, and cost, and is properly made with a prescriber rather than from a comparison table.

Clinical Eligibility Is Not Insurance Coverage

This is the distinction that surprises people most, and the one that causes the most frustration. Meeting the clinical criteria means a prescriber can reasonably write the prescription. It does not mean anyone other than you will pay for it. Clinical eligibility and insurance coverage are separate gates, and the second is frequently the harder one to clear — particularly for the weight-management indication, which many plans have historically excluded even while covering the identical molecule for diabetes.

The reasons are partly historical and partly economic. Weight-loss medications were long viewed by payers as lifestyle or cosmetic treatments rather than medical necessities, and that legacy lingers in plan design even as the disease framing has gained ground. The medications are also expensive, and the eligible population is very large, so the aggregate cost to an insurer of covering every qualifying member is substantial. The result is a patchwork: some plans cover weight-management GLP-1s with few hurdles, some cover them only after documented attempts at lifestyle change or a step through cheaper agents, and some exclude the weight indication entirely while routinely covering the diabetes one.

Where coverage exists, it is commonly gated by prior authorization — a process in which the insurer requires documentation that you meet specific criteria before agreeing to pay. These criteria can be stricter than the clinical label: a plan might require a BMI of 30 rather than 27, documented comorbidities, evidence of a prior supervised weight-loss attempt, or enrolment in a lifestyle programme alongside the medication. Navigating this is a meaningful part of access in practice. The mechanics of the two challenges are covered in getting GLP-1 covered by insurance and, for the documentation process specifically, in prior authorization tips. None of this is financial advice, and coverage rules change frequently; your plan's current formulary is the authoritative source.

Supply has added a further layer. Periodic shortages, driven by demand outstripping manufacturing, have at times meant that even people who are both clinically eligible and covered could not reliably fill a prescription. The lesson is that eligibility is necessary but not sufficient: clearing the medical bar is the start of access, not the end of it.

Contraindications: When a GLP-1 Is Not Appropriate

Some factors take a person out of contention regardless of BMI or comorbidity, because the risk of the medication outweighs the benefit. These are well-established items of label information, and a careful prescriber screens for every one of them before writing a prescription.

The most absolute contraindication concerns a specific, rare thyroid cancer. GLP-1 receptor agonists are contraindicated in people with a personal or family history of medullary thyroid carcinoma (MTC), and in people with multiple endocrine neoplasia syndrome type 2 (MEN2), a genetic condition that predisposes to MTC. The concern derives from rodent studies in which GLP-1 agonism was associated with thyroid C-cell tumours; whether this translates to humans is unproven, but the contraindication is precautionary and firm. A family history of medullary thyroid cancer is something a prescriber will ask about directly, and an affirmative answer ordinarily ends the conversation about these drugs.

A history of pancreatitis calls for caution. Pancreatitis has been reported in people taking GLP-1 agonists, and while a causal link at the population level remains debated, a prior episode raises the stakes enough that prescribers weigh it carefully and many will avoid the class where the history is significant. Anyone who develops severe, persistent abdominal pain while taking one of these medications is advised to seek prompt medical attention, because pancreatitis is a recognised, if uncommon, serious adverse event.

Other cautions are relative rather than absolute. Gallbladder disease warrants attention, because rapid weight loss of any kind raises the risk of gallstones, and these medications produce rapid weight loss. Severe gastrointestinal disease, such as gastroparesis (already-delayed stomach emptying), interacts poorly with a drug whose mechanism is to slow gastric emptying further. People with a history of severe hypoglycaemia, or taking insulin or sulfonylureas, need careful management because combining therapies raises the risk of blood sugar dropping too low. And known hypersensitivity to the specific agent is, as with any drug, a contraindication. None of these is a number on a scale; all of them can override an otherwise comfortable BMI-based eligibility.

Pregnancy and Reproductive Considerations

GLP-1 receptor agonists are not recommended during pregnancy. Weight loss is not a goal during pregnancy, and there is insufficient safety data to support use; animal studies have raised concerns about reproductive harm. Standard guidance is that these medications should be stopped before a planned pregnancy — typically a couple of months before attempting to conceive, reflecting the long half-life of the weekly agents — and discontinued promptly if pregnancy is discovered. Anyone who could become pregnant and is starting one of these drugs should discuss reliable contraception and pregnancy planning with their prescriber as part of the eligibility conversation.

There is an additional, practical wrinkle worth flagging. Because these medications slow gastric emptying, they can reduce the absorption of oral medications taken at the same time, and there has been specific attention to whether they may lower the effectiveness of oral contraceptives — particularly during dose escalation with some agents. This is exactly the kind of detail a prescriber will raise, and it is a reason the prescribing conversation should be candid and complete rather than transactional. Breastfeeding is similarly an area where data are limited and caution applies.

How the Prescribing Conversation Works

Assuming you clear the criteria and have no contraindications, what does actually getting a prescription involve? The process centres on a clinical assessment, whether in person or, increasingly, by telehealth. The clinician confirms your BMI, reviews your weight history and any weight-related conditions, takes a full medical and family history — with particular attention to the contraindications above — and reviews your current medications for interactions. Baseline measurements such as blood pressure and relevant bloodwork are commonly part of this. The conversation should also cover realistic expectations: what magnitude of weight loss is typical, how long it takes, what happens on stopping, and the side effects to anticipate.

Expectation-setting deserves emphasis, because eligibility is the beginning of a long relationship with a medication, not a finish line. The trials describe averages with wide individual variation — some people lose a great deal, others relatively little, and a minority do not respond meaningfully. Setting goals against the evidence rather than against marketing or social media is part of starting well; the realistic picture is laid out in realistic weight loss goals on GLP-1. A good prescriber also frames the treatment as ongoing management of a chronic condition rather than a short course, because the biology of weight regain means that stopping tends to be followed by regain — the medication counters the body's defence of its prior weight rather than removing it.

Telehealth has become a major route of access, widening reach for people without easy access to in-person obesity-medicine services, though the quality and thoroughness of providers vary widely. A responsible telehealth service still performs the full screen — BMI, history, contraindications, interactions — rather than treating the prescription as a formality, and it provides genuine follow-up for titration and side-effect management. What to look for, and what to avoid, is covered in best telehealth GLP-1 prescriptions. Whatever the route, prescribing does not end at the first script: the titration schedule, the monitoring, and the periodic reassessment of whether the medication is doing what was intended are all part of competent care.

Finally, eligibility is not static. People who do not qualify today may qualify later if their weight or health changes, and the criteria themselves continue to evolve as evidence accumulates and as regulators extend approvals — to adolescents, to cardiovascular risk reduction, and potentially to further conditions. For a wider map of how access fits alongside mechanism, side effects, and outcomes, the GLP-1 science cluster collects the related guides in one place.